# Numedii

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/numedii

- Industry: Pharmaceuticals
- Headquarters: Menlo Park, US
- Website: numedii.com
- Total disclosed funding: $5.5M
- Latest round: Series A (May 13, 2015)
- Investors on record: 6

## About

Numedii is a biotechnology company that leverages advanced data analytics to enhance drug discovery and development processes, utilizing AI and deep learning to provide innovative solutions for pharmaceutical and healthcare sectors.Founded in 2008 and headquartered in Menlo Park, US, Numedii focuses on accelerating drug discovery through its proprietary analytics platform. The company raised a total of USD 2.00 mn in Series A funding on May 13, 2015, with participation from investors including Claremont Creek Ventures, Lightspeed Venture Partners, and others. The CEO and founder, Tarangini Deshpande, has played a pivotal role in the firm’s strategic direction.Numedii specializes in advanced data-driven solutions aimed at accelerating drug discovery and development processes. Their core product offerings include a proprietary platform that integrates artificial intelligence with deep learning methodologies to analyze vast biological datasets. This innovative technology is designed to identify novel drug candidates and optimize existing therapies, addressing critical challenges in the pharmaceutical and biotechnology sectors. Numedii targets a diverse client base, which includes pharmaceutical companies, research institutions, and healthcare providers primarily in North America and Europe. By facilitating the identification of viable therapeutic options more efficiently, Numedii aims to significantly reduce the time and costs associated with bringing new treatments to market.Numedii's revenue model is structured around B2B transactions, primarily involving subscription-based services and licensing agreements with pharmaceutical and biotech companies. Clients engage with Numedii through tailored partnerships that grant access to their advanced analytics platform, enhancing drug development processes. Financial transactions typically involve multi-year contracts, which include initial setup fees followed by recurring subscription charges corresponding to the level of service and data access provided. Numedii's flagship service is instrumental in aiding clients to streamline their R&D efforts, resulting in significant cost savings and improved outcomes in drug development initiatives.Numedii plans to utilize the USD 2.00 mn raised in Series A funding to further develop its proprietary platform and expand its market reach. The company is currently in the process of designing new features for its analytics platform, which are expected to launch by late 2023. Additionally, Numedii aims to penetrate new markets in Asia and South America by 2024, specifically targeting pharmaceutical firms and research institutions in those regions.

## Funding rounds

- Series A, May 13, 2015, $2M — Lightspeed Venture Partners, Claremont Creek Ventures, Seraph Group, TSVC, StartX
- Series A, Jun 26, 2013, $3.5M — Lightspeed Venture Partners, Claremont Creek Ventures, Life Science Angels, Inc.

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- Claremont Creek Ventures (https://capitalatlas.ai/funds/claremont-creek-ventures) — Series A
- Life Science Angels, Inc. — Series A
- Seraph Group (https://capitalatlas.ai/funds/seraph-group) — Series A
- TSVC (https://capitalatlas.ai/funds/tsvc) — Series A
- StartX — Series A